tapentadol (nucynta) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tapentadol is the first US FDA-approved centrally acting analgesic having both μ-opioid receptor agonist and noradrenaline (norepinephrine) reuptake inhibition activity with minimal serotonin reuptake inhibition. Tapentadol is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.3004 - $1.0306

United States

$1.9957 - $30.0171
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3-((1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl)phenol | bn-200 | cg5503 | cg 5503 | cg-5503 | nucynt | nucynta | nucynta er | palexia | r331333 | tapentadol | tapentadol hcl | tapentadol hydrochloride

Organizations (29)

Research & Development (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (36)

Approved Indications (4)


 

Acute Pain

Chronic Pain

Neuralgia

Pain

Experimental Indications - Clinical Trial Phases 1-4 (36)


 

Acute Pain (Phase 4)

Analgesics, Opioid (Phase 4)

Arthralgia (Phase 3)

Arthritis (Phase 3)

Arthroplasty (Phase 3)

Back Pain (Phase 4)

Bone Diseases (Phase 2)

Bunion (Phase 3)

Chronic Pain (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetic Neuropathies (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Hallux Valgus (Phase 3)

Healthy Volunteers (Phase 1)

Heart (Phase 1)

Hyperalgesia (Phase 1)

Hysterectomy (Phase 3)

Intestinal Neoplasms (Phase 4)

Joint Diseases (Phase 3)

Low Back Pain (Phase 4)

Neoplasms (Phase 3)

Neuralgia (Phase 4)

Neuralgia, Postherpetic (Phase 2)

Nociceptive Pain (Phase 3)

Osteoarthritis (Phase 3)

Osteoarthritis, Hip (Phase 3)

Osteoarthritis, Knee (Phase 4)

Pain ()

Pain Measurement (Phase 3)

Pain, Postoperative (Phase 4)

Peripheral Nervous System Diseases (Phase 4)

Pharmacokinetics (Phase 1)

Postoperative Complications (Phase 3)

Sciatica (Phase 3)

Tapentadol (Phase 3)

Visceral Pain (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 66
  • # of Trial Organizations: 20

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue